Camurus
631
SEK
+5,34 %
CAMX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
8 investorer følger denne virksomhed
www.camurus.com/sv/investerare
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Omsætning
1,72 mia.
EBIT %
30,63 %
P/E
81,11
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
CAMX
Daglig lav / høj pris
584,5 / 631
SEK
Markedsværdi
37,11 mia. SEK
Aktieomsætning
114,04 mio. SEK
Volumen
186 t
Seneste videoer
Finanskalender
Delårsrapport
07.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Sandberg Development AB | 35,0 % | 35,2 % |
Fjärde AP-fonden | 4,5 % | 4,5 % |
JP Morgan Chase Bank | 3,6 % | 3,6 % |
Swedbank Robur Fonder | 3,3 % | 3,4 % |
Avanza Pension | 2,9 % | 3,0 % |
Fredrik Tiberg | 2,8 % | 2,8 % |
State Street Bank and Trust | 2,6 % | 2,6 % |
Handelsbanken Fonder | 2,6 % | 2,6 % |
The Bank of New York Mellon SA/NV | 1,5 % | 1,5 % |
Norges Bank | 1,2 % | 1,2 % |
ViserAlle indholdstyper
Camurus AB: Camurus' Interim Report Third Quarter 2024
Camurus AB: Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools